Insider Trading Alert - BMY, ACN, REGN, ACAS And MXIM Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 4, 2014, 131 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $408.12 to $109,651,973.50.

Highlighted Stocks Traded by Insiders:

Bristol-Myers Squibb Company (BMY) - FREE Research Report

Cornelius James M who is Director at Bristol-Myers Squibb Company sold 100,000 shares at $48.90 on Feb. 4, 2014. Following this transaction, the Director owned 373,393 shares meaning that the stake was reduced by 21.12% with the 100,000-share transaction.

The shares most recently traded at $48.15, down $0.75, or 1.56% since the insider transaction. Historical insider transactions for Bristol-Myers Squibb Company go as follows:

  • 24-Week # shares sold: 100,000

The average volume for Bristol-Myers Squibb Company has been 8.2 million shares per day over the past 30 days. Bristol-Myers Squibb Company has a market cap of $80.1 billion and is part of the health care sector and drugs industry. Shares are down 7.92% year-to-date as of the close of trading on Tuesday.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. The stock currently has a dividend yield of 2.96%. The company has a P/E ratio of 26.7. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMY - FREE

TheStreet Quant Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact